ImmunityBio, Inc.
IBRXNASDAQHealthcare● Active
$7.17
+$0.25(+3.61%)
Market Cap$7.5B
P/E Ratio—
52W High$12.43
52W Low$1.95
ImmunityBio, Inc. (IBRX) · Cash Flow
Annual, quarterly, or TTM views · SEC 10-K & 10-Q via FMP · adjust period and M/B/T below.
FMP · IBRX · as of 2026-06-10
Financial statements
Operating CF · CapEx · Free Cash Flow
| Breakdown | 2025-12 | 2024-12 | 2023-12 | 2022-12 | 2021-12 |
|---|---|---|---|---|---|
| Operating Activities | |||||
| Net Income | $0.00B | ($0.41B) | ($0.58B) | ($0.42B) | ($0.35B) |
| Depreciation & Amort. | $0.00B | $0.02B | $0.02B | $0.03B | $0.01B |
| Stock-Based Comp. | $0.00B | $0.03B | $0.05B | $0.04B | $0.06B |
| Change in Working Capital | ($0.05B) | ($0.02B) | $0.00B | ($0.02B) | ($0.02B) |
| Net Cash from Operations | ($0.30B) | ($0.39B) | ($0.37B) | ($0.34B) | ($0.27B) |
| Investing Activities | |||||
| Capital Expenditure | ($0.00B) | ($0.01B) | ($0.03B) | ($0.08B) | ($0.03B) |
| Purchases of Investments | ($0.24B) | ($0.14B) | ($0.01B) | $0.00B | $0.00B |
| Sales of Investments | $0.10B | $0.14B | $0.01B | $0.00B | $0.00B |
| Net Cash from Investing | ($0.15B) | ($0.01B) | ($0.03B) | $0.03B | ($0.08B) |
| Financing Activities | |||||
| Common Stock Repurchased | $0.00B | $0.00B | $0.00B | ($0.00B) | ($0.00B) |
| Dividends Paid | $0.00B | $0.00B | $0.00B | $0.00B | $0.00B |
| Debt Issued / Repaid | $0.00B | $0.10B | $0.26B | $0.17B | $0.34B |
| Net Cash from Financing | $0.40B | $0.28B | $0.56B | $0.23B | $0.51B |
| Free Cash Flow | |||||
| Free Cash Flow | ($0.31B) | ($0.40B) | ($0.40B) | ($0.42B) | ($0.31B) |
| FCF Margin %(computed) | -272.56% | — | — | — | — |
Data source: Financial Modeling Prep · Last updated: 2026-06-10 · USD · B
Explore more ImmunityBio, Inc. data
About ImmunityBio, Inc. (IBRX) Cash Flow Statement
ImmunityBio, Inc. generated operating cash flow of ($0.30B) and free cash flow of ($0.31B) for 2025 — a FCF margin of -272.56%. Capital expenditure was ($0.00B).
Frequently asked questions
IBRX · 4 questionsImmunityBio, Inc. generated free cash flow of ($0.31B) for 2025, up 22.4% year-over-year.
IBRX free cash flowFCF margincash flow yield
· Source: FMP /stable/cash-flow-statement · SEC EDGAR Form 10-K & 10-Q · As of 2026-06-10